

## Recombinant Human FGL1 (C-6His)

Catalog #	EPT232
Expression Host	Human Cells
DESCRIPTION	Recombinant Human Fibrinogen-like Protein 1 is
	produced by our Mammalian expression system and
	the target gene encoding Leu23-Ile312 is expressed
	with a 6His tag at the C-terminus.
Accession	Q08830
Synonyms	Fibrinogen-like protein 1; FGL1; HP-041; Hepassocin;
	HFREP-1; LFIRE-1
Mol Mass	35 KDa
AP Mol Mass	35 KDa, reducing conditions
Purity	Greater than 90% as determined by reducing
	SDS-PAGE.
Endotoxin	Less than 0.1 ng/ $\mu$ g (1 EU/ $\mu$ g) as determined by LAL
	test.
FORMULATION	Supplied as a 0.2 $\mu$ m filtered solution of 20mM
	Tris-HCl, 300mM NaCl, 10% Glycerol, 2mM EDTA, pH
	8.0.



+86-27-59760950 ELKbio@ELKbiotech.com www.elkbiotech.com 23-2, No.388 Gaoxin 2nd Road,Wuhan East Lake Hi-tech Development Zone, Hubei , P.R.C



RECONSTITUTION

SHIPPING

The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.

STORAGEStore at  $\leq$ -70°C, stable for 6 months after receipt.Store at  $\leq$ -70°C, stable for 3 months under sterile<br/>conditions after opening.

Please minimize freeze-thaw cycles.

BACKGROUND Fibrinogen-like protein 1(FGL1) is also known as HP-041, Hepassocin, HFREP-1, LFIRE-1, is а liver-specific secreted protein belonging to the fibronogen superfamily, whose members share a fibrinogen domain at their C-termini. It is secreted by the liver and functions as a mitogen for hepatocytes. Hepassocin may play a role in the development of hepatocellular carcinomas. Hepassocin is а disulfide-linked homodimeric protein with а C-terminal fibrinogen domain. It is reported that it is a major immune inhibitory ligand of LAG-3.




+86-27-59760950

ELKbio@ELKbiotech.com

www.elkbiotech.com

23-2, No.388 Gaoxin 2nd Road, Wuhan East Lake Hi-tech Development Zone, Hubei , P.R.C





+86-27-59760950 EL

ELKbio@ELKbiotech.com

www.elkbiotech.com

23-2, No.388 Gaoxin 2nd Road, Wuhan East Lake Hi-tech Development Zone, Hubei , P.R.C